

Glattbrugg, 29 March 2023

Sole Source Confirmation Letter

In this letter, we confirm that Cytosurge AG is the sole source of FluidFM® technology and specifically the FluidFM® OMNIUM system.

FluidFM® is a unique technology which combines micro-machined nanopipettes for femtoliter liquid handling with piconewton force feedback. This allows to deposit and intake minute liquid amounts as well as the control of microscopic object by suction and overpressure. Applications range from nanolithography to colloidal studies, biophysical analysis of cells, as well as single cell injection and isolation.

Cytosurge AG holds a portfolio of intellectual property rights concerning FluidFM® including several patents, trademarks and copyrights. We hold the following patents:

- Method for spatially manipulating a microscopic object and device for conducting said method, WO2011103691A1, EP 2539720 A1, US9162778, US2013010503
- Probe arrangement, US2008302960, US 7870616 B2, EP1990626A1
- Probe arrangement for exchanging in a controllable way liquids with micro-sized samples of material like biological cells, EP2318137A1, US 8986626 B2, US20110124027, WO2010012423A1, WO2010012423A8
- Touch-screen based scanning probe microscopy, US 20150160260 A1, PCT/EP2013/000716

We are the only organization in the world with the unique technical competence, expertise, experience as well as proprietary knowledge of FluidFM® as-well-as the design and manufacture of the FluidFM® OMNIUM system.

Sincerely,

Simon Egli
Chief Commercial Officer
Cytosurge AG

